Endpoints for randomized controlled clinical trials for COVID-19 treatments

Background: Endpoint choice for randomized controlled trials of treatments for novel coronavirus-induced disease (COVID-19) is complex. Trials must start rapidly to identify treatments that can be used as part of the outbreak response, in the midst of considerable uncertainty and limited information...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical trials (London, England) England), 2020-10, Vol.17 (5), p.472-482
Hauptverfasser:	Dodd, Lori E, Follmann, Dean, Wang, Jing, Koenig, Franz, Korn, Lisa L, Schoergenhofer, Christian, Proschan, Michael, Hunsberger, Sally, Bonnett, Tyler, Makowski, Mat, Belhadi, Drifa, Wang, Yeming, Cao, Bin, Mentre, France, Jaki, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Betacoronavirus Clinical trials Computer simulation Coronavirus Infections - drug therapy Coronavirus Infections - epidemiology Coronaviruses COVID-19 Evaluation Health services Humans Medical research Medical treatment Mortality Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - epidemiology Randomized Controlled Trials as Topic - methods SARS-CoV-2 Statistical methods Statistics Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!